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Intestinal pathobionts that escape into the periphery can cause serious morbidity and death. In this issue of
Immunity, Hasegawa et al. (2014) show that the host’s protectivemeasures against such events include inter-
leukin-22-driven systemic elimination of pathobionts via complement regulation.An extraordinary number and variety of
microbes populate our gastrointestinal
system. During evolution, the host and
the gut microbiota establish a complex
relationship that is now acknowledged
as being well beyond mere coexistence
such that it has an explicit mutualistic
nature whereby the intestinal flora is often
considered a microbial organ placed
within the gut. The gut microbiota regu-
lates host energy balance and mediates
normal production of several vitamins
and hormones as well as water adsorp-
tion. Moreover, intestinal bacteria are
critically required for the development
of gut-associated lymphoid organs and
protect the host from colonization with
invading harmful microbial species and
pathogens throughout life.
However, maintaining the integrity of
the intestinal barrier and sustaining a
homeostatic balance among the dynamic
microbiota are key to health because
the normal gut flora contains several
potentially virulent species, called patho-
bionts, that can cause disease when they
escape into the host’s periphery (Hase-
gawa et al., 2012). For example, the com-
mon treatment of hospitalized patients
with broad-spectrum antibiotics resultsin alterations of the normal intestinal
microbiota and fosters overgrowth of
pathogenic Gram-positive spore-forming
Clostridium difficile, which is normally
prevented by commensals. C. difficile-
derived toxins then damage the intestinal
epithelium, which leads to translocation
of intestinal bacteria into the extrain-
testinal space and causes infectious
diarrhea and pseudomembranous colitis.
Thus, C. difficile infection is a disease
with a largely iatrogenic cause and with
worrying rising incidence and increasing
severity of pathogenesis: elimination of
C. difficile with vancomycin and/or
metronidazole is ineffective in about
4%–7% of patients, and C. difficile
infection can be fatal specifically in the
frail, elderly, or immunocompromised.
Importantly, recent work in the field
strongly indicates that commensals and/
or pathobionts that have breached the
compromised epithelial barrier during
C. difficile infection and accumulate
in extraintestinal organs and tissues
contribute to disease pathogenesis and
mortality (Hasegawa et al., 2012). How-
ever, the underlying mechanisms sup-
porting peripheral pathobiont dissemi-
nation and the measures taken by thehost’s immune system are unanswered
questions.
The current study by Hasegawa et al.
(2014) delivers some important mecha-
nistic insights into these complex events
in C. difficile infection. The authors have
examined the role of interleukin-22 (IL-
22) in C. difficile infection in protec-
tion against secondary pathobiont sepsis
and survival. Using an established animal
model, the study first observed strikingly
lower survival rates in Il22/ mice than
in wild-type control mice after C. difficile
infection. This was shown to be associ-
ated with the translocation of ordinarily
‘‘commensal’’ bacteria (or pathobionts)
of the predominant g-enterobacterial
type to extraintestinal sites, such as the
liver and lung, only in IL-22-deficient
mice. These mice, however, could be
rescued either by elimination of patho-
bionts by targeted antibiotics or through
administration of recombinant IL-22.
Although the central role of IL-22 in the
prevention of pathobiont translocation
has previously been acknowledged (Aujla
et al., 2008; Basu et al., 2012; Sonnenberg
et al., 2012), a novel mechanistic link be-
tween IL-22 and enhanced pathobiont
killing was then elegantly identified by, October 16, 2014 ª2014 Elsevier Inc. 511
Figure 1. A Functional Axis between IL-22 andComplement Protects theHost fromSystemic
Pathobiont Dissemination after Damage to the Intestinal Border
Dysbiosis in the gut can lead to uncontrolled C. difficile growth and subsequent intestinal epithelial dam-
age by C. difficile-derived toxins. This allows translocation of commensals and pathobionts into the extra-
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data sets for highly expressed genes in
colonic tissue after IL-22 administration.
This revealed that complement C3, a
hub protein for activation of complement
pathways, was among the most strongly
IL-22-induced proteins. Subsequent in
vitro and in vivo experiments with C3-defi-
cient or -depleted animals, cells, and
serum samples then allowed the authors
to develop a model in which C. difficile-
infection-induced generation of IL-22
provoked increased C3 production and
secretion by the liver in a STAT3-depen-
dent manner. This led to a substantial
increase in systemic serum amounts of
C3, which in turn mediated enhanced op-
sonization of translocated commensals
and pathobionts via C3b and their killing
and removal by neutrophils and macro-
phages (Figure 1). Thus, the authors
demonstrate for the first time a critical
role for IL-22 not only in host protection
at the intestine but also in systemic clear-
ance of pathobionts.
Importantly, Hasegawa et al. (2014)
demonstrated that individual strains of
the translocated pathobionts displayed
different sensitivities to C3b opsonization
and complement-mediated uptake by
neutrophils and that the acquisition of
pathobiont complement resistance was
the likely cause of their successful popu-
lation of peripheral organs and the fatal
complications in C. difficile infection.
These findings might have clinical impli-
cations given that the mechanistic under-
standing of complement resistance in
commensals and/or pathobionts could
provide urgently needed novel treatment
options to limit the severe pathogen-
esis observed in cases of uncontrolled
C. difficile infection.intestinal environment, which induces the local
generation of IL-1b and IL-22 and recruitment
and activation of neutrophils and other phagocytes
that contain and remove bacteria. Pathobionts
escaping further into the periphery are normally
C3b opsonized and tagged for removal by an IL-
22-driven increase in systemic liver-derived C3
production. Phagocytic uptake and destruction of
opsonized bacteria are then mediated by tissue-
resident and/or tissue-infiltrating neutrophils and
macrophages (because complement activation in-
duces recruitment of phagocytes into tissues).
However, absent or reduced amounts of IL-22
generation (preventing the increase in protective
systemic C3 amounts) and translocation of patho-
bionts resistant to complement-mediated phago-
cytic uptake can both lead to failure of pathobiont
elimination in peripheral organs.
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PreviewsIL-22 is an evolutionarily old cytokine,
and it seems plausible for a link to exist
with the complement pathway, itself
one of the oldest components of our im-
mune system. Complement proteins are
acute phase proteins that are dynami-
cally regulated, especially at times of
high consumption, such as sepsis. The
evidence that induction of IL-22 subse-
quently leads to increases in C3 synthe-
sis could be viewed as a counterbalanc-
ing mechanism to the increase in C3
consumption during C. difficile infection
and pathobiont septicemia, and defining
exactly how this occurs could be an
interesting future study. The authors
suggest that this novel functional axis
between IL-22 and C3 could also be ex-
ploited therapeutically via the controlled
modulation of IL-22 amounts. Indeed,
although IL-22 is required for the clear-
ance of certain pathogens (Aujla et al.,
2008) and plays a central role in the
maintenance of the epithelial barrier
(Sonnenberg et al., 2012; Zheng et al.,
2008) and in the initial establishment of
host-microbiota symbiosis (Goto et al.,
2014), it appears to have a rather modest
direct impact on immune cells, and
therefore modulation of IL-22 makes it
less likely to induce the highly toxic
side effects often seen in cytokine ther-
apy. However, it is also apparent that
the biology of IL-22 is not yet fully under-
stood and explored and that this cyto-
kine mediates strongly context-specific
effects. For example, a recent study
demonstrated that IL-22 tips the balance
between pathogenic and commensal
bacteria in favor of a pathogen and
promotes Salmonella enterica serovar
Typhimurium infection (Behnsen et al.,
2014) and that circulating IL-22 mediates
a strong acute phase response (Liang
et al., 2010)—thus, further increasing IL-
22 in such settings could be detrimental.
Furthermore, the cellular source of IL-22
also varies and depends on specific
experimental settings and infection
models. IL-22 is classically described
as derived from activated T cells, and a
recent study identified T helper 22 cells
as the key IL-22 source for host protec-
tion against enteropathogenic bacteria(Basu et al., 2012). IL-22 production by
intestinal innate lymphoid and NKp46+
cells has also been described. On the
other hand, in the current study by Hase-
gawa et al. (2014), tissue concentrations
of IL-22 were still high in Rag1–/– mice,
and the authors suggest that IL-22 is
largely produced by neutrophils in their
model (Hasegawa et al., 2014). Thus,
defining the specific induction modes of
IL-22 secretion by distinct cell popula-
tions in C. difficile and other infection
models will be important.
The novel connection between IL-22
and complement touches on another
area of traditionally high interest for
potential pharmacological modulation:
because complement dysregulation con-
tributes to many disease states, it has
been under investigation for therapeutic
targeting for decades. However, many of
the attempts in controlling complement
directly have been hampered by our
slow understanding that complement,
like IL-22 and many other cytokines
and growth factors, is a functionally
similarly ambiguous system. Comple-
ment is only recently being considered
by the wider immunology community as
having functions extending beyond pro-
tective immunity to include cell genera-
tive, degenerative, and regenerative
processes. In addition, it is now emerging
that the role of ‘‘classic’’ systemic liver-
derived complement is functionally
different from locally or intracellularly
generated and activated complement.
Hasegawa et al. (2014) show here that
C. difficile-infection-driven circulating IL-
22 induces an increase in C3 secretion
by the liver, and they have focused on
the role of hepatic systemic C3 induction
during pathobiont and commensal clear-
ance in the periphery. However, aside
from hepatic C3 induction, the authors
also observed that the addition of recom-
binant IL-22 induced C3 mRNA expres-
sion in other organs, including the spleen,
lung, and intestines. Although this finding
was not further functionally explored here,
it aligns with our developing understand-
ing that many, if not most, effector sys-
tems exert ‘‘location-specific’’ functions.
Thus, a careful future analysis of nonhe-Immunity 41patic induction of C3 production during
C. difficile infection, specifically at the
intestinal location where the epithelial bar-
rier is breached and where commensal
and/or pathobiont release induces an
immediate local immune reaction, might
unearth additional dimensions in this
new functional partnership between IL-
22 and complement in pathobiont control.
It could also potentially extend to barrier
maintenance itself given that complement
has been shown to promote intestinal
wound healing (Cardone et al., 2011). In
sum, the data presented in this work
pave the way for future studies to explore
and possibly exploit the exact mecha-
nisms by which IL-22 and complement
partner up for protective host environ-
mental border patrol.
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